Ibex Medical Analytics and Medipath engage in a strategic partnership to unleash the power of Artificial Intelligence in Medipath’s pathology labs in France

4 Sep, 2019

Back

Tel Aviv, Israel and Frejus, France, September 4, 2019 –Ibex Medical Analytics, a pioneer in Artificial Intelligence-based cancer diagnostics, and Medipath, the largest network of private pathology labs in France, announce today a partnership, designed to introduce artificial intelligence to the workflow in Medipath’s pathology labs and co-develop the next generation of Ibex’s product suite.

Ibex Medical Analytics provides an Artificial Intelligence (AI)-based decision support platform for pathology labs, empowering pathologists to deliver quick, objective and accurate diagnoses. The company recently raised $11 million toward the expansion of its offering and commercial footprint.

The engagement with Medipath follows collaborations in additional geographies, including a strategic partnership with Maccabi Healthcare Services, Israel’s second largest HMO, and a collaboration with UPMC (The University of Pittsburgh Medical Center) in the United States. It is another step toward global integration of Ibex’s AI-based tools for cancer diagnosis in pathology labs. Ibex Second ReadTM System for prostate cancer, the first-ever AI-driven diagnostics application in clinical use in a pathology lab, has already demonstrated significant clinical value by alerting pathologists to cancer cases.

Medipath and Ibex will present the initial outcomes from the partnership at the European Congress of Pathology, held next week in Nice, France, with an abstract titled ”Performance of an AI-based cancer diagnosis system in France’s largest network of pathology institutes”, presented on Tuesday, September 10th. Ibex will hold a booth at the congress (#A16).

“Medipath is the largest network of pathology labs in France. As part of our commitment and dedication to our patients and customers, we strive to utilize state-of-the-art technologies to produce quick and accurate results, providing unsurpassed levels of quality, reliability and efficiency. We strongly believe in the value proposition of artificial intelligence in healthcare and specifically in pathology, and are proud to partner with Ibex Medical Analytics, which is at the heart of the development and implementation of artificial intelligence for pathology labs and cancer diagnoses”, says Olivier Vire, Chairman, Medipath.

“We are excited to work with Medipath on introducing AI-based algorithms to their clinical workflow, enabling the Medipath network to retain its leadership position in the pathology market and to ensure the best quality of service for their patients and customers”, says Joseph Mossel, Ibex Medical Analytics CEO.

Back

About IBEX

IBEX is the leader in AI-powered cancer diagnostics in pathology. We empower physicians to provide every patient with an accurate, timely and personalized cancer diagnosis. Our Galen™ platform is deployed worldwide, supporting pathologists and providers with AI-insights that help improve the quality and accuracy of diagnosis, reduce turnaround times and boost productivity.

About IBEX

IBEX is the leader in AI-powered cancer diagnostics in pathology. We empower physicians to provide every patient with an accurate, timely and personalized cancer diagnosis. Our Galen™ platform is deployed worldwide, supporting pathologists and providers with AI-insights that help improve the quality and accuracy of diagnosis, reduce turnaround times and boost productivity.